Prospective Observational Swiss Cohort Study to Investigate Long-term Pulmonary and Extrapulmonary Effects of COVID-19.
COVID-19 is a coronavirus induced viral pneumonia leading to Acute Respiratory Distress
Syndrome. Previous coronavirus infections (SARS and MERS) led to pulmonary fibrosis in up to
30%. Prospective evaluation of lung abnormalities and pulmonary fibrosis after COVID-19
infection is crucial as novel treatments against lung fibrosis of different etiologies are
available. No data on pulmonary longterm effects in COVID-19 survivors are currently
available. The nation-wide Swiss COVID-19 lung group establishes a meticulously characterized
prospective cohort study on pulmonary long-term sequela of patients living in Switzerland.
Other: COVID-19
Research project in which biological material is sampled and health-related personal data are collected and used for further research. Coded data are used.
Other Name: Array
Inclusion Criteria:
- Signed written informed consent.
- All adult patients with COVID-19 over 18 years.
Exclusion Criteria:
- Severe mental or physical disability precluding informed consent or compliance with
the protocol for prospective data collection.
- Pregnancy.
St. Claraspital AG - Department of Pulmonary Medicine
Basel, Switzerland
Universtiy Hospital Bern (Inselspital), Department of Pulmonary Medicine - Lead Center
Bern, Switzerland
University and Hospital of Fribourg
Fribourg, Switzerland
Hôpitaux Universitaires de Genève - Service de Pneumologie
Genève, Switzerland
CHUV - Service de Pneumologie
Lausanne, Switzerland
Clinica Moncucco
Lugano, Switzerland
Hôpital du Valais - Service de Pneumologie
Sion, Switzerland
Kantonspital St. Gallen - Klinik für Pneumologie und Schlafmedizin Lungenzentrum
St. Gallen, Switzerland
Universitätsspital Zürich - Klinik für Pneumologie
Zürich, Switzerland
Manuela Funke-Chambour, MD, Principal Investigator
University Hospital Bern, Department of Pulmonary Medicine - Lead Center